Evidence mapPaperPMID 32812348Full record

ReviewAmerican journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics2020

Genetic feedback for psychiatric conditions: Where are we now and where are we going.

Morgan N Driver, Sally I-Chun Kuo, Danielle M Dick

Abstract readReview
In one paragraph

Review in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Public engagement with genomics.Wellcome open research · 2023
    Review
  10. The Promise and Peril of Genetics.Current directions in psychological science · 2022
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. How do experts in psychiatric genetics view the clinical utility of polygenic risk scores for schizophrenia?American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Morgan N DriverDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.ORCID 0000-0001-6738-0667
Sally I-Chun KuoDepartment of Psychology, Virginia Commonwealth University, Richmond, Virginia, USA.ORCID 0000-0002-6192-1001
Danielle M DickDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.ORCID 0000-0002-1636-893X

Funding

NIAAA NIH HHS K02 AA018755NIAAA NIH HHS R34 AA027347NIH HHS K02AA018755NIH HHS R34AA027347
6 · The paper itself

Abstract

Genome-wide association studies are rapidly advancing our understanding of the genetic architecture of complex disorders, including many psychiatric conditions such as major depression, schizophrenia, and substance use disorders. One common goal of genome-wide association studies is to use findings for enhanced clinical prediction in the future, which can aid in identifying at-risk individuals to enable more effective prevention screening and treatment strategies. In order to achieve this goal, we first need to gain a better understanding of the issues surrounding the return of complex genetic results. In this article, we summarize the current literature on: (a) genetic literacy in the general population, (b) the public's interest in receiving genetic test results for psychiatric conditions, (c) how individuals react to and interpret their genotypic information for specific psychiatric conditions, and (d) gaps in our knowledge that will be critical to address as we move toward returning genotypic information for psychiatric conditions in both research and clinical settings. By reviewing extant studies, we aim to increase awareness of the potential benefits and consequences of returning genotypic information for psychiatric conditions.

Indexed as

Attitude to HealthGenetic Predisposition to DiseaseGenetic TestingGenome-Wide Association StudyGenotypeHealth Knowledge, Attitudes, PracticeHumansMajor Depressive DisorderMental DisordersMental HealthMultifactorial InheritanceSchizophreniaSubstance-Related Disordersgenetic literacygenetic testingpersonalized feedbackpsychiatric disorderspsychiatric genetics

Identifiers

PMID32812348
PMCPMC8108123

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.